mecasermin
Orphan Drug Cold Chain RequiredFDA Approved, EMA Approved
Description
Mecasermin is a recombinant human insulin-like growth factor-1 used for growth failure in children with severe primary IGF-1 deficiency or growth hormone gene deletion. It has been investigated for use in Silver-Russell syndrome patients with IGF-1 deficiency and growth retardation. The drug promotes linear growth by stimulating skeletal, cell, and organ growth.
Indications & Therapeutic Use
severe primary IGF-1 deficiency, growth hormone gene deletion with neutralizing antibodies, growth failure in children
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
mecasermin
| Generic Name | mecasermin |
| Brands | 1 brand available |
| Active Ingredient | recombinant human insulin-like growth factor-1 (rhIGF-1) |
| Drug Class | severe primary IGF-1 deficiency |
| Manufacturer | Ipsen |
| Dosage Forms | subcutaneous injection, 10 mg/mL solution |
| Medical Code | H01AC03 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00001562 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes